[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
October 12, 2011

Clinical Trials of Orphan Drugs for Cancer

Author Affiliations

Author Affiliation: National Organization for Rare Disorders, Danbury, Connecticut (psaltonstall@rarediseases.org).

JAMA. 2011;306(14):1545-1546. doi:10.1001/jama.2011.1463

To the Editor: Dr Kesselheim and colleagues found that pivotal trials for orphan cancer drugs often have fewer patients and use different trial designs than trials for drugs for more prevalent cancers.1 Rare diseases by definition have small patient populations; trials in such populations will commonly have fewer patients than those for more prevalent diseases. Recruitment of participants for such studies is challenging, and trials of new agents for orphan diseases may, of necessity, be nonrandomized and open label because of the size of the patient populations available for the studies and the nature of the diseases.